首页> 外文期刊>BMC Health Services Research >Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers
【24h】

Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers

机译:老年小细胞肺癌和转移性非小细胞肺癌老年患者的人口统计学,治疗方式,医疗保健利用和费用比较

获取原文
       

摘要

Background Limited data exist regarding real-world treatment patterns, resource utilization, and costs of extensive-stage small cell lung cancer (esSCLC) among elderly patients in the United States. While abundant data are available on treatment patterns in metastatic non-small cell lung cancer (mNSCLC), to our knowledge no data exist comparing costs and resource use between patients with esSCLC or mNSCLC. Methods We retrospectively analyzed administrative claims data (2000-2008) of patients aged ≥65 years from the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database. Patients were selected on the basis of having newly diagnosed esSCLC (n=5,855) or mNSCLC (n=24,090) during 1/1/2000-12/31/2005, and were required to have received cancer-directed therapy. Survival and other measures were compared between esSCLC and mNSCLC patients using Kaplan-Meier log-rank and univariate chi-square and t-tests. Study measures were followed from first diagnosis date of either esSCLC or mNSCLC until the earlier of death or end of the database. Results Survival between the cohorts did not differ significantly: mean of 10.4 months for esSCLC patients versus 11.1 months for mNSCLC; median survival was 7.4 months versus 5.9 months. A higher percentage of mNSCLC patients (vs. esSCLC) received radiation therapy (75.6% vs. 65.4%; P Conclusions Lifetime total and disease-related costs per patient were high. Increased use of chemotherapy, supportive care therapies (including growth factors), and disease-related hospitalizations were observed in esSCLC patients as compared with mNSCLC patients. Disease-related and all-cause costs for esSCLC also exceeded those of mNSCLC, except for hospice and skilled nursing services. Survival and per-patient costs for both groups underscore the unmet medical need for more effective therapies in patients with esSCLC or mNSCLC.
机译:背景技术在美国老年患者中,关于现实世界的治疗模式,资源利用以及广泛期小细胞肺癌(esSCLC)的费用的数据有限。尽管可获得关于转移性非小细胞肺癌(mNSCLC)治疗模式的大量数据,但据我们所知,尚无数据可比较esSCLC或mNSCLC患者之间的成本和资源使用情况。方法我们回顾性分析了从链接的监测,流行病学和最终结果(SEER)-医疗保险数据库中≥65岁的患者的行政索赔数据(2000-2008年)。根据在1/1 / 2000-12 / 31/2005期间新诊断出的esSCLC(n = 5,855)或mNSCLC(n = 24,090)来选择患者,并要求他们接受癌症定向治疗。使用Kaplan-Meier对数秩和单变量卡方检验和t检验比较esSCLC和mNSCLC患者的生存率和其他指标。从esSCLC或mNSCLC的首次诊断日期开始,直至死亡或数据库结束之前,一直采取研究措施。结果队列之间的生存期无显着差异:esSCLC患者平均为10.4个月,而mNSCLC平均为11.1个月;中位生存期为7.4个月,而5.9个月。接受放射治疗的m​​NSCLC患者(相对于esSCLC)的比例更高(75.6%比65.4%; P结论)每位患者的终生总费用和疾病相关费用较高。化疗,支持治疗(包括生长因子)的使用增加, esSCLC患者与mNSCLC患者相比,住院和疾病相关的住院费用;除了临终关怀和熟练的护理服务外,esSCLC的疾病相关和全因费用也超过了mNSCLC。 esSCLC或mNSCLC患者对更有效疗法的医疗需求尚未得到满足。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号